Clinical trial NCT02014142: A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma
Official title: A Phase 2 Single-Masked, Randomized Study of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ocular Hypertension
Open-Angle Glaucoma
Lead sponsor: Mati Therapeutics Inc.
Sponsor class: INDUSTRY
First posted: 2013-12-18
Enrollment: 86
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Determine efficacy of the latanoprost punctal plug. Effect of configuration of L-PPDS placement on efficacy will also be examined.


Eligibility criteria: Inclusion Criteria:

1. Male or female, 18 years or older at the time of the screening examination
2. Subject diagnosed with bilateral OAG or OH
3. Subject IOP is currently controlled (\< 21 mmHg) with a topical prostaglandin or in conjunction with one other topical ocular hypotensive drug, not including any fixed-combination formulations (i.e., Cosopt, Combigan, Azarga, etc.) for at least one month or more
4. Subject who has lower and upper puncta \> 0.5 mm and \< 0.9 mm (pre-dilation) in both eyes
5. Subject must be able and willing to read, comprehend and give Authorization for Use/Disclosure of Health Information (HIPAA) and informed consent
6. Subject must be willing to comply with study instructions, dosing (if applicable), agree to make all office appointments, and complete the entire course of the study
7. Women of child-bearing potential must not be pregnant or lactating, must have a negative pregnancy test at screening and must be practicing an adequate method of birth control, including intrauterine device (IUD); oral, dermal ("patch"), implant or injected contraceptives; tubal ligation; or barrier methods with spermicide
8. Subject has a central corneal thickness of \> 500 μm and \< 600 μm in study eye
9. Subject has a BCVA or pinhole visual acuity (Snellen) of 20/100 or better in both eyes

Exclusion Criteria:

1. Subject with a history of non-response to topical prostaglandin eye drops for OAG/OH
2. Subject with angle-closure glaucoma, neovascular glaucoma, traumatic glaucoma or iridocorneal endothelium syndrome in either eye
3. Subject with a known sensitivity to latanoprost, timolol, fluorescein, topical anesthetic, silicone, any inactive ingredient of the L-PPDS or any other products required for the study procedures
4. Subject with a history of intolerance to topical beta-blocker therapy
5. Subject with \> 0.8 vertical cup or completely notched optic nerve head rim in either eye
6. Subject with any functionally significant visual field loss or progressive field loss within the last year in either eye
7. Subject with a history of complications, AEs, trauma or disease in the nasolacrimal area, whether or not it was due to punctal plug wear, including but not limited to dacryocystitis, inflammation or canaliculitis in study eye
8. Subject with structural lid abnormalities (i.e., ectropion, entropion) in study eye
9. Subject with an active lid disease in either eye (i.e., moderate or severe blepharitis, meibomianitis) that requires medical treatment
10. Subject with a history of chronic/recurrent inflammatory eye disease (i.e., scleritis, uveitis, herpes keratitis) in either eye
11. Subject who would require the use of any ocular topical medication(s), an over-the counter drop(s), ointment(s) or gel(s), other than the study ocular hypotensive medication(s) in either eye during the study period
12. Subject who has had any ophthalmic surgical procedures (i.e., glaucoma laser, minimally invasive glaucoma surgery, cataract, refractive, etc.) in study eye within the last six months or will require ophthalmic surgery before completing the study
13. Subject with a history of penetrating keratoplasty in study eye
14. Subject who is incapable of instilling ocular drops into his or her eyes
15. Subject requiring the use of a contact lens in either eye at any time during the study period
16. Subject with advanced diabetic retinopathy, branch retinal vein occlusion or central retinal vein occlusion in either eye
17. Subject with a history of macular edema in either eye
18. Subject currently on any systemic medication \[i.e., beta-blocker, carbonic anhydrase inhibitors, corticosteroids (including dermal), etc.\], that may have an effect on the subject's IOP, or who will require its use during the study period (Note: an inhaled steroid, systemic beta-blocker or β-adrenoceptor antagonist may be permitted, providing the subject has maintained a stable dosage regimen for at least the last three months)
19. Subject contraindicated to therapy with a beta-blocker (i.e., history or presence of bradycardia, untreated congestive heart failure, untreated second- or third-degree heart block, sino-atrial block, myasthenia gravis, cardiogenic shock, history or presence of bronchial asthma, bronchial hyperreactivity, severe chronic obstructive pulmonary disease, or history of bronchospasm)
20. Subject with an uncontrolled systemic disease or a medical condition that may increase the risk associated with study participation or administration of study treatment or that may interfere with the interpretation of study results (e.g., autoimmune disease if the subject is on chronic medications and has ocular involvement; host-versus-graft disease)
21. Subject currently participating or has participated within the last 30 days prior to the start of this study in a drug, device or other investigational research study

Primary outcomes:
measure: IOP change from baseline and the primary analysis time point will be the IOP assessment at Week 12
timeFrame: 12 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Chandler
country: United States
facility: Arizona Eye Center
state: Arizona
city: Phoenix
country: United States
facility: Arizona Glaucoma Specialists
state: Arizona
city: Torrance
country: United States
facility: Wolstan & Goldberg Eye Associates
state: California
city: Cape Coral
country: United States
facility: Argus Research at Cape Coral Eye Center
state: Florida
city: Fort Myers
country: United States
facility: Eye Associates of Fort Myers
state: Florida
city: Indianapolis
country: United States
facility: Indiana Universtiy - Eugene and Marilyn Glick Eye Institute Ophthalmology Center
state: Indiana
city: Edgewood
country: United States
facility: Cincinnati Eye Institute
state: Kentucky
city: St. Joseph
country: United States
facility: Great Lakes Eye Care
state: Michigan
city: Bloomington
country: United States
facility: Chu Vision Institute
state: Minnesota
city: St. Louis
country: United States
facility: Ophthalmology Associates
state: Missouri
city: Washington
country: United States
facility: Comprehensive Eye Care, Ltd.
state: Missouri
city: Las Vegas
country: United States
facility: Abrams Eye Institute
state: Nevada
city: Lynbrook
country: United States
facility: Ophthalmic Consultants of Long Island
state: New York
city: Slingerlands
country: United States
facility: Dr. Steven T. Simmons
state: New York
city: Philadelphia
country: United States
facility: Philadelphia Eye Associates
state: Pennsylvania
city: Phildelphia
country: United States
facility: Wills Eye Hospital
state: Pennsylvania
city: Maryville
country: United States
facility: University Eye Surgeons
state: Tennessee
city: Memphis
country: United States
facility: Total Eye Care
state: Tennessee
Study officials:
References: